Template:Plasma levels and binding potential of flutamide and bicalutamide during first week
Plasma levels and binding potential of flutamide and bicalutamide during first week
| Day |
Total levels (ng/mL) |
Free levels (ng/mL) |
Ratios
|
| Bicalutamide |
Flutamidea |
Bicalutamide |
Flutamidea |
Free |
Binding potentialb
|
| 1 |
901 |
940 |
36.0 |
66 |
0.55 |
2.18
|
| 2 |
1613 |
1500 |
64.5 |
105 |
0.61 |
2.46
|
| 3 |
2345 |
1500 |
93.8 |
105 |
0.89 |
3.57
|
| 4 |
2969 |
1500 |
118.8 |
105 |
1.13 |
4.53
|
| 7 |
4259 |
1500 |
170.4 |
105 |
1.62 |
6.49
|
| Notes: During first week of treatment. Dosages not provided. Footnotes: a = As 2-hydroxyflutamide (the active form of flutamide). b = Assumes, on the basis of ligand binding assays, that bicalutamide possesses 4-fold greater affinity for the androgen receptor than 2-hydroxyflutamide. Sources: [1]
|
- ^ Blackledge GR (1996). "Clinical progress with a new antiandrogen, Casodex (bicalutamide)". Eur. Urol. 29 Suppl 2: 96–104. doi:10.1159/000473847. PMID 8717470.